Home › Funds › Arrowpoint Investment Partners (Singapore) Pte. Ltd. › VRTX

Arrowpoint Investment Partners (Singapore) Pte. Ltd. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Arrowpoint Investment Partners (Singapore) Pte. Ltd. reported holding 44,805 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$23.4M, representing 5.37% of its reported portfolio and ranking #8 among its reported holdings. Arrowpoint Investment Partners (Singapore) Pte. Ltd. has disclosed VRTX holdings in 5 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)44.80K sh
Reported value held$23.42M
Portfolio Weight5.37%
First reportedQ4 2024
Last changeNew
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s VRTX position evolved

Arrowpoint Investment Partners (Singapore) Pte. Ltd. first disclosed a stake in VRTX in Q4 2024 at 3,900 shares (US$1.6M). The position peaked in Q3 2026 at 44,805 shares, worth US$23.4M. Across 5 filings, Arrowpoint Investment Partners (Singapore) Pte. Ltd. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 44,805 shares valued at US$23.4M. Notable position changes include a 88% trim in Q1 2025 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 3.90K $1.57M New
Q1 2025 457 $221.56K Reduce
Q4 2025 3.36K $1.53M New
Q1 2026 3.41K $1.52M Add
Q3 2026 44.80K $23.42M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Arrowpoint Investment Partners (Singapore) Pte. Ltd. held VRTX?

Arrowpoint Investment Partners (Singapore) Pte. Ltd. has disclosed VRTX holdings in 5 of the last 8 reported quarters, going back to Q4 2024.

What is Arrowpoint Investment Partners (Singapore) Pte. Ltd.'s current position in VRTX?

As of Q3 2026, Arrowpoint Investment Partners (Singapore) Pte. Ltd. holds 44.80K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $23.42M, representing 5.37% of its reported portfolio and ranking #8.

Has Arrowpoint Investment Partners (Singapore) Pte. Ltd. been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Arrowpoint Investment Partners (Singapore) Pte. Ltd. newly opened its position in VRTX. The position peaked in Q3 2026 at 44.80K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.